Surv BioPharma

Japan · Biotech

Surv BioPharma develops oncolytic virus therapies for cancer.

Product

Surv BioPharma develops genetically engineered viruses intended to replicate selectively in cancer cells and destroy them. Its platform uses a survivin-responsive promoter to control viral replication.

The Kagoshima University spinout is developing Surv.m-CRA-1 for rare bone and soft-tissue cancers. It is also working on a next-generation virus incorporating immune-related genes. The company was established in Japan in 2022 to commercialise research led by Ken-ichiro Kosai.

Funding history

4 rounds · 4 with disclosed amounts
AnnouncedRoundAmountInvestors
Phased AMED GRiT support≤¥1.7BJapan Agency for Medical Research and Development (AMED) — Participant
Series B second close¥670MFFG Venture Fund III — ParticipantFukuoka Jisho — ParticipantInnovation Kyoto 2021 Investment Limited Partnership — ParticipantOita VC Success Fund No. 7 — ParticipantSagin Venture Capital Fund No. 6 — ParticipantTOHO HOLDINGS CO — Participant
AMED ecosystem programme support≤¥2.7BJapan Agency for Medical Research and Development (AMED) — Participant
Series B first close¥1.5BKII No.3 Impact Fund — LeadDaiwa Taiwan-Japan BioVenture Investment Limited Partnership II — ParticipantFujita TT Impact Fund I — ParticipantHigin Venture Fund No. 3 Investment Limited Partnership — ParticipantKagoshima Value Up Investment Limited Partnership — ParticipantNVCC Fund 10 — ParticipantQB Fund II — Participant
Sourcesprtimes.jp ↗survbiopharma.co.jp ↗